Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Study to Evaluate Safety, Tolerability, and Biomarker Efficacy of E2814 With Concurrent Lecanemab Treatment in Subjects With Early Alzheimer's Disease

NCT06602258 is registered in ClinicalTrials.gov with Eisai Inc. as lead sponsor.

NCT NCT06602258
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06602258 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Study to Evaluate Safety, Tolerability, and Biomarker Efficacy of E2814 With Concurrent Lecanemab Treatment in Subjects With Early Alzheimer's Disease
Lead sponsor
Eisai Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
September 30, 2024
Completion date
August 18, 2027
Enrollment
105 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer's disease